When Urokinase Was Gone: Commentary on Another Year of Thrombolysis Without Urokinase

Journal of Vascular and Interventional Radiology

Volumn 15, Issue 1 I, 2004, Pages 1-5

  Gates, Julia ^a   Hartnell, George G ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN DERIVATIVE; PLASMINOGEN ACTIVATOR; RETEPLASE; UROKINASE;

BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; DRUG EFFICACY; DRUG FATALITY; DRUG MANUFACTURE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HUMAN; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUESTIONNAIRE; TREATMENT INDICATION;

EID: 1642576960     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.RVI.0000106384.63463.A5     Document Type: Note

References (16)

1. Zoon KC. F.D.A. Important Drug Warning Letter, 1/25/99. Center for Biologics Evaluation and Research. Available at: http://www.fda.gov/ cber/ltr/abb012599.htm
2. Hartnell GG, Gates JG. The case of Abbokinase and the FDA: the events leading to the suspension of Abbokinase supplies in the United States. J Vasc Interv Radiol 2000; 11:841-847.
3. Gates J, Hartnell GG. When the urokinase was gone. Scientific exhibit, 85th Scientific Assembly and Annual Meeting RSNA, Chicago, December. Radiology 1999; 213:519.
4. Marder V. Letter to Sidney M. Wolfe MD, February 5, Quoted in Public Citizen Letter to the FDA, HRG Publication no. 1473, February 1999; 10: 1999. See http://www.citizen.org/publications/release.cfm?ID=6671.
5. Arepally A, Hofmann LV, Kim HS, et al. Weight-based rt-PA thrombolysis protocol for acute native arterial and bypass graft occlusions. J Vasc Interv Radiol 2002; 13:45-50.
6. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol 2000; 11:279-287.
7. Funaki B, Ha TV. Catheter directed thrombolysis in 2002: what have we learned? New Dev Vasc Dis 2002; 3:7-9.
8. McNamara TO, Dong P, Chen J, et al. Bleeding complications associated with the use of rt-PA versus r-PA for peripheral arterial and venous thromboembolic occlusions. Tech Vasc Interv Radiol 2001; 4:92-98.
9. Ouriel K. Urokinase and the US Food and Drug Administration. J Vasc Surg 1999; 30:957-958.
10. Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusion. J Vasc Interv Radiol 2000; 11:411-420.
11. Semba CP, Murphy TP, Bakal CW, Calis KA, Matalon TA. Thrombolytic therapy with use of alteplase (rt-PA) in peripheral arterial occlusive disease: review of the clinical literature. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol 2000; 11:149-161.
12. Ouriel K, Katzen B, Mewissen M, et al. Reteplase in the treatment of peripheral arterial and venous occlusions: a pilot study. J Vasc Interv Radiol 2000; 11:849-854.
13. Ouriel K, Gray B, Clair DG, Olin J. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol 2000; 11:295-298.
14. Yakovlev S, Makogonenko E, Kurochkina N, Nieuwenhuizen W, Ingham K, Medved L. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 2000; 39: 15730-15741.
15. Laird JR. Pharmacologic therapies in the treatment of peripheral vascular disease: clinical experience with reteplase, a third-generation thrombolytic. J Invasive Cardiol 2000; 12(suppl B): 27B-32B.
16. Davidian MM, Powell A, Benenati JF, Katzen BT, Becker GJ, Zemel G. Initial results of reteplase in the treatment of acute lower extremity arterial occlusions. J Vasc Interv Radiol 2000; 11:289-294.